SNC-Lavalin's Isotek Systems announced on 13 April that its sales agreement with nuclear company TerraPower had been expanded to further refine thorium (Th-229).
The new agreement “will support TerraPower in its cancer treatment research by delivering an enhanced purified product and add to the over $90 million taxpayer dollars saved under this innovative public private partnership”, Isotek said.
To read more please visit:
Source: Nuclear Engineering